摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-chloro-2-phenylquinoline-4-carboxylic acid | 174636-90-9

中文名称
——
中文别名
——
英文名称
3-chloro-2-phenylquinoline-4-carboxylic acid
英文别名
——
3-chloro-2-phenylquinoline-4-carboxylic acid化学式
CAS
174636-90-9
化学式
C16H10ClNO2
mdl
——
分子量
283.714
InChiKey
YGJOMCUDGVMOMS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    50.2
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-chloro-2-phenylquinoline-4-carboxylic acid草酰氯potassium carbonate 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 24.0h, 生成 (S)-N-(1-phenylpropyl)-3-chloro-2-phenylquinoline-4-carboxamide
    参考文献:
    名称:
    Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human Neurokinin-3 Receptor. 2. Identification of (S)-N-(1-Phenylpropyl)-3-hydroxy-2- phenylquinoline-4-carboxamide (SB 223412)
    摘要:
    Optimization of the previously reported 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonist 14, with regard to potential metabolic instability of the ester moiety and affinity and selectivity for the human neurokinin-3 (hNK-3) receptor, is described. The ester functionality could be successfully replaced by the ketone (31) or by lower alkyl groups (Et, 21, or n-Pr, 24). Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. All of the chemical groups introduced at this position, with the exception of halogens, increased the hNK-3 binding affinity, and compounds 53 (3-OH, SE 223412, hNK-3-CHO binding K-i = 1.4 nM) and 55 (3-NHz, hNK-3-CHO binding K-i = 1.2 nM) were the most potent compounds of this series. Selectivity studies versus the other neurokinin receptors (hNK-8-CHO and hNK-1-CHO) revealed that 53 is about 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 mu M. In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca2+ mobilization in CHO cells stably expressing the hNK-3 receptor), while in vivo this compound showed oral and intravenous activity in NK-3 receptor-driven models (senktide-induced behavioral responses in mice and senktide-induced miosis in rabbits). Overall, the biological data indicate that (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (53, SE 223412) may serve as a pharmacological tool in animal models of disease to assess the functional and pathophysiological role of the NK-3 receptor and to establish therapeutic indications for non-peptide NK-3 receptor antagonists.
    DOI:
    10.1021/jm980633c
  • 作为产物:
    描述:
    2-氨基苯乙酮盐酸氢氧化钾copper(l) chloride 、 sodium nitrite 作用下, 以 乙醇 为溶剂, 生成 3-chloro-2-phenylquinoline-4-carboxylic acid
    参考文献:
    名称:
    Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human Neurokinin-3 Receptor. 2. Identification of (S)-N-(1-Phenylpropyl)-3-hydroxy-2- phenylquinoline-4-carboxamide (SB 223412)
    摘要:
    Optimization of the previously reported 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonist 14, with regard to potential metabolic instability of the ester moiety and affinity and selectivity for the human neurokinin-3 (hNK-3) receptor, is described. The ester functionality could be successfully replaced by the ketone (31) or by lower alkyl groups (Et, 21, or n-Pr, 24). Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. All of the chemical groups introduced at this position, with the exception of halogens, increased the hNK-3 binding affinity, and compounds 53 (3-OH, SE 223412, hNK-3-CHO binding K-i = 1.4 nM) and 55 (3-NHz, hNK-3-CHO binding K-i = 1.2 nM) were the most potent compounds of this series. Selectivity studies versus the other neurokinin receptors (hNK-8-CHO and hNK-1-CHO) revealed that 53 is about 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 mu M. In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca2+ mobilization in CHO cells stably expressing the hNK-3 receptor), while in vivo this compound showed oral and intravenous activity in NK-3 receptor-driven models (senktide-induced behavioral responses in mice and senktide-induced miosis in rabbits). Overall, the biological data indicate that (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (53, SE 223412) may serve as a pharmacological tool in animal models of disease to assess the functional and pathophysiological role of the NK-3 receptor and to establish therapeutic indications for non-peptide NK-3 receptor antagonists.
    DOI:
    10.1021/jm980633c
点击查看最新优质反应信息

文献信息

  • MET kinase inhibitors
    申请人:Borzilleri M. Robert
    公开号:US20070078140A1
    公开(公告)日:2007-04-05
    The present invention is directed to compounds having the formula I or II: including salts thereof, and methods for using them for the treatment of cancer.
    本发明涉及具有以下化学式I或II的化合物:包括其盐,并且使用它们用于治疗癌症的方法。
  • A novel synthesis of 3-halo-2-phenylquinoline-4-carboxylic acids
    作者:Luca F. Raveglia、Giuseppe A. M. Giardina、Mario Grugni、Roberto Rigolio、Carlo Farina
    DOI:10.1002/jhet.5570340235
    日期:1997.3
    3-bromo-2-phenylquinoline-4-carboxylic acids were obtained in good yields through a novel procedure, entailing the synthesis of the 3-amino intermediate and the subsequent replacement of the amino group with chlorine or bromine, according to the Sandmeyer reaction.
    通过一种新颖的方法,以高收率获得了3-氯和3-溴-2-苯基喹啉-4-羧酸,需要合成3-氨基中间体,然后用氯或溴取代氨基。桑德迈尔反应。
  • MET KINASE INHIBITORS
    申请人:Bristol-Myers Squibb Company
    公开号:EP1937682B1
    公开(公告)日:2015-08-12
  • US7482458B2
    申请人:——
    公开号:US7482458B2
    公开(公告)日:2009-01-27
  • US7547782B2
    申请人:——
    公开号:US7547782B2
    公开(公告)日:2009-06-16
查看更多